Sales Support Specialist

Why join EnginZyme?

Why now: cosmetics, food and pharma makers are under pressure to make cleaner ingredients, and biomanufacturing is gaining momentum. If EnginZyme scales its patented EziG enzyme platform, enzymes could become a standard way many everyday goods get made at industrial scale. The Stockholm biotech has raised $42M in total, most recently an $8M round backed by Sofinnova Partners and Active Capital, and Aymeric de Gantès now leads it as CEO.

JustBacked's take, based on EnginZyme's own site and its funding and hiring data.